How do I talk to family and friends about diabetes? Is this MY burden to bear? Are loved ones a “diabetes bright spot” or “diabetes police”?

A decision on Novo Nordisk’s faster-acting mealtime insulin is expected in late 2017; also launched in Canada, Germany, and the UK, and coming soon to more European...

The diaTribe Foundation convenes key diabetes experts to discuss glycemic outcomes beyond A1C on July 21, 2017, in Bethesda, MD

How to overcome the most frustrating diabetes landmine

“Adam, what do you eat when you’re on a plane?” My six go-to strategies from hundreds of flights and airports

Ginger Vieira and Jennifer Smith’s month-to-month guide for managing blood sugars, nutrition, exercise, and mental health during pregnancy

The lame food advice at Adam Brown's diagnosis, why it didn’t work, and Adam's #1 Bright Spot solution

A six-week study of Tandem’s first automated insulin delivery device with Dexcom’s G5 CGM

Expected in 2017. Plus, the latest in the pipeline, including concentrated insulin systems and the Horizon Automated Glucose Control System

First trial next month, launch expected in 2-3 years; Dexcom CGM included; a big commitment to diabetes tech innovation from an insulin company

A workshop hosted by the JDRF and Helmsley Charitable Trust brought together leaders in the field to discuss opportunities and advances in the treatment and possible...

The diaTribe Foundation and TCOYD host discussion at ADA focusing on access, outcomes beyond A1c, and future expectations

A recent trial comparing once-weekly GLP-1 agonists semaglutide and Trulicity found improved A1c and double the weight loss with semaglutide

How it works and why it could help with exercise challenges. Plus, how diaTribe readers can try it for free

What does donated diabetes data tell us about time-in-range across different age groups?

Comparing Medtronic’s MiniMed 670G to injections and pumps in people with type 1 diabetes, with and without CGM; enrollment to open in May at some trial locations

A currently-enrolling trial is investigating a new arthritis medication along with type 2 diabetes drug Victoza, aiming to preserve insulin production in people with...

Trial results testing sotagliflozin and Farxiga in type 1 diabetes show greater A1c lowering and weight loss, plus continued conversation about small risk of DKA

The FDA decision on Novo Nordisk’s basal insulin is based on positive safety and efficacy data of Tresiba versus other basal insulins

Studies highlight reduced hypoglycemia risk for people with type 2 diabetes who switch to “next-gen” basal insulins Toujeo or Tresiba